I’m an entrepreneur and investor. Currently, I’m the Founder and CEO of AdoraPet Biosciences, a biotech company creating healthier pets, and MAnaging Director of Ascendant Venture, a family office/venture studio investing in seed stage startups.

Previously, I was Founder and CEO of KindredBio (NASDAQ:KIN), a biotech company that develops therapeutics for pets, which was acquired by Elanco. Previously, I was the CEO of the first U.S. nonprofit drug development company, Institute for OneWorld Health, CEO of Oxigene (NASDAQ:OXGN), and Head of Global Development for Elan. Before that, I served in various clinical roles at Genentech, including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of products at Genentech. I was previously an Associate Professor at UCSF School of Medicine, where I taught drug development to students, fellows, and junior faculty.

I am a physician by training (Harvard Medical School, Barnes Hospital), and a lawyer by training as well (albeit in British law, at Oxford, under a Rhodes Scholarship). In 2006, BusinessWeek named me as one of 99 youngest public company CEOs in the United States.

You can see my full background at LinkedIn.